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ABSTRACT: In the management of coronary artery disease (CAD) most advances have 
concerned improvements in catheter-based interventional techniques and complex 
pharmacotherapy, with an emphasis on time, which unfortunately, cannot always 
achieved. However, simple measures with reassuring benefit that can be performed even 
by non-cardiologists have been largely overlooked, or understated. These include limiting 
reperfusion injury by remote ischaemic conditioning (RIPC), a powerful protective 
mechanism that can be elicited by the transient occlusion of blood flow to a limb with a 
blood pressure cuff. More controversially, glucose-insulin-potassium (GIK) therapy in early 
ST elevation myocardial infarction (STEMI) has the potential to improve outcomes 
especially when timely restoration of vessel patency is difficult to achieve. This systematic 
review will evaluate the role of these therapies as adjuncts to revascularisation for 
treating coronary artery disease either electively or during an acute coronary 
syndrome. 
 
Objectives: To determine if RIPC or GIK therapy for CAD leads to reduced mortality 
(primary objective), infarct size, cardiac enzyme release or major adverse cardiac and 




Methods: The search strategy identified 100 articles from 2 databases, Cochrane and 
PubMed. Following review of the titles, 85 articles were excluded, leaving 15 studies for 
full-text review of which 6 articles were included in the final subset. 
 
 
Results: RIPC as part of adjunctive therapy for patients undergoing revascularisation for 
coronary artery disease leads to reduced mortality, cardiac enzyme release and improved 




hospital mortality, left ventricular infarct size and composite end point of cardiac arrest, 
 




Conclusions: RIPC and GIK are valuable adjunctive therapies for patients undergoing 
revascularisation for coronary artery disease. More large scale, multi-centred, placebo 














Coronary artery disease (CAD) is among the leading causes of mortality worldwide 
contributing to at least 3 million deaths per year.¹ From being an illness seen 
predominantly in the developed world it has become increasingly common in developing 
countries where progressive urbanisation has led to a scourge of lifestyle diseases and 
consequently, risk factors for coronary artery disease.2 In South Africa, coronary artery 





The spectrum of coronary artery disease ranges from chronic stable angina to the acute 
coronary syndromes, namely unstable angina, non ST elevation myocardial infarction 
(NSTEMI) and ST elevation myocardial infarction (STEMI).3 Of these, STEMI portends the 
most severe short term prognosis as it implies complete occlusion of a coronary artery 
which ultimately leads to myocardial necrosis.4 The timely revascularisation of an occluded 
vessel is therefore a key component of therapy.5,6 This can be achieved by thrombolysis or 
coronary angiography. In South Africa and other developing countries where resources are 
scarce, delays to achieve definitive revascularisation plague the health care system and 
angiographic facilities are not easily accessible, the role of adjunctive strategies to improve 
outcomes while still being easy to perform, safe and cost effective become especially 
important. Furthermore, revascularisation itself carries a risk of reperfusion injury due to 
the abrupt restoration of blood flow to previously ischaemic myocardium.7 
 
Of the extensive list of potentially cardio-protective adjunctive strategies, other than 
standard pharmacotherapy, that target the biochemical pathways involved in CAD and 
reperfusion injury many have yielded consistently negative results (Table 1).8 This study 
however will evaluate remote ischemic conditioning and glucose-insulin-potassium 








Table 1. TESTED CARDIOPROTECTIVE STRATEGIES IN ACS8 Outcome 










Anti-leucocyte interventions (anti-CD18 monoclonal antibodies) Negative 
 
* This table excludes standard pharmacotherapy for ACS such thrombolytic therapies, 
anticoagulation, antiplatelet agents, beta-blockers, angiotensin converting enzyme inhibitors, 




Reperfusion injury and ischaemic preconditioning 
 
 
Revascularisation of an occluded coronary artery is an important target for therapy in 
STEMI.5,6 Recent emphasis has been on achieving the shortest door to needle or balloon 
times but this has proven difficult to attain in developed, and more so, in developing 
countries.1,2,9 Furthermore, there has been growing evidence to suggest that recanalisation 
of an occluded artery is an important contributor to myocardial damage accounting for up 
to 50% of the final infarct size.7 This effect is termed “ischaemic reperfusion injury” which 
refers to the paradoxical myocardial, vascular or electrophysiological dysfunction that is 
induced by the restoration of blood flow to previously ischaemic tissue. It is seen in many 
organs and has been demonstrated in both animal and human models.10 Reperfusion 
injury in the heart may be manifest by reperfusion arrhythmias, endothelial damage with 
microvascular dysfunction, myocardial stunning and worsening myocardial infarction.11 
The mechanism, although not well defined, is thought to be contributed to by oxidative 
stress from an abrupt re-oxygenation of ischaemic tissue as well as intracellular calcium 
overload & acid-base disturbances.11 
 
Ischaemic preconditioning, on the other hand, is an intervention that attempts to reduce 
the potentially negative sequelae associated with reperfusion by intentionally evoking brief 
periods of ischaemia. It is applied either locally to coronary vasculature with catheter 
balloon inflations or in a much more simple manner “remotely” with cycles of blood 
pressure cuff inflations to about 200mmHg for 5 minutes before the anticipated 
reperfusion. The latter is therefore termed remote ischaemic preconditioning (RIPC).  The 
precise nature of the transducing signal from remote tissue to target organ is unclear, 
however, humoral or neuronal response mechanisms have largely been implicated.12  In 
animal studies adenosine, bradykinin and calcitonin gene related peptide have been 
identified as important mediators in this neurohormonal stimulus.13 
 
Another proposed, although less well established theory, is the induction of counter-
regulatory kinases via the reperfusion injury salvage kinase (RISK) and the survival activator 
enhancement pathway (SAFE) pathways in multiple organs.14,15  The cytokine tumor 
necrosis factor alpha (TNFα) plays a crucial role in this process. Although TNFα is thought 
to contribute to myocardial dysfunction in ischaemia and heart failure it paradoxically 
initiates the activation of these pathways, which serve to enhance mitochondrial stability 
by opening ATP dependent potassium channels & by closing mitochondrial permeability
9  
transition pores. 15 This is a critical step in preventing ATP depletion and cardiomyocyte death 












RISK indicates reperfusion injury salvage kinase; SAFE, survival activator enhancement; 
ATP, adenosine triphosphate. The cytokine tumor necrosis factor alpha (TNFα) plays a 







Reperfusion injury and glucose-insulin-potassium therapy 
 
 
Glucose-insulin-potassium (GIK) administered at the time of infarction has attracted 
interest after being introduced by Sodi-Pallares in 1962 when it was used primarily as a 
polarising solution to stabilise myocyte membranes and correct ECG abnormalities.16 The 
implications were unclear as to the potential long-term effect of GIK however in the single 
patient who was treated early in the Sodi-Pallares study, there was electrocardiographic 
improvement suggesting a therapeutic benefit for GIK. 
 
Opie observed that high FFA levels adversely affected cardiac rhythm and function.17 He 
explained that the metabolic damage during acute myocardial infarction was caused by 
high levels of circulating fatty acids (FFAs) which were elevated as a result of the release of 
counter-regulatory catecholamines and cytokines, which stimulate lipolysis.18 He thereafter 
expanded the concept by delineating the effect of suppressing high FFA levels and the 
major pathways in which GIK could be metabolically protective.19 
 
Although lower levels of FFA are an important myocardial fuel in the fasted state, 
abnormally high FFA levels were demonstrated by Mjos in 1971 to be harmful because 
their metabolism led to myocardial oxygen wastage.20 Fatty acid intermediates inhibited 
glycolysis and led to higher levels of lactate as well as hydrogen ions, which reduce cardiac 
contractility, lead to diastolic dysfunction and potentiate arrhythmias.21,22 
 
The rationale for GIK would be ultimately to reduce circulating FFAs and thereby 
attenuate their deleterious metabolic effects.23,24 GIK has been shown to enhance 
glycolytic flux within cells and increase ATP production, which maintains membrane 
pump and ion homeostasis.25  This leads to greater contractile function and cellular 
viability of the myocyte.26 Insulin, a key component of GIK, suppresses lipase and 
intracellular cAMP in adipose tissues thereby disrupting the B-adrenergic signaling during 
catecholamine-mediated lipolysis (Figure 2).27 It helps correct the untoward effect of 
hyperglycaemia, a consequence of the acute catecholamine elevation in AMI, which 
potentiates abnormal vascular responsiveness, thrombus formation and platelet 




Moreover, through many complex mechanisms insulin has anti-inflammatory, anti- 
 








Figure 2. Mechanism of benefit for insulin in ischaemia 
 
 
NF-KB indicates nuclear factor kappa beta; ICAM, intracellular adhesion molecules; CRP, C- 







Table 2. Mechanism of adverse effects of sustained hyperglycaemia in ischaemia28 
Endothelial dysfunction 
Platelet hyper-reactivity 
Increased cytokine activation 
Increased lipolysis & free fatty acid levels 
Reduced glycolysis & glucose oxidation 
Osmotic diuresis, potentially reduced cardiac output 
Increased oxidative stress (increased myocardial apoptosis) 
Impaired micro-circulatory function (no-reflow phenomenon) 




The role of potassium in GIK is to ensure myocardial cell membrane stability by preventing 
hypokalaemia, since the infusion would cause potassium to move intracellularly. The 
administration of exogenous potassium in safe doses therefore guards against this.29,30. 
 
 
A revival of the GIK concept has best been described in the recent review by Grossman et 
al. in which the cellular effects of GIK have been elaborated.31 In a variety of animal and 
clinical models they supported the idea that GIK helps normalize intra-mitochondrial 
energy production by inhibiting the FFA-induced abnormalities. This correlates clinically to 








The traditional management of STEMI has ignored the role for metabolic modulation5,6. 
Reperfusion injury as a result of revascularisation confers an obvious risk, which may be 
attenuated with appropriate intervention. While there are many potential treatments 
(Table 1) in this regard, this review evaluates remote ischaemic preconditioning (RIPC) and 
glucose-insulin-potassium (GIK) as promising adjunctive therapies to revascularisation, 
which may prevent reperfusion injury, as suggested by both animal and human studies. The 
results from previous studies however have been unclear, as they have not administered 
RIPC or GIK early (before myocyte necrosis occurs). 
 
 
The aims of this systematic review was therefore to summarize and quantitate (1) the risk 
of mortality in patients who underwent RIPC or GIK infusions and,  (2) the risk of clinical 
outcomes (i.e. a reduction in infarct size, cardiac enzyme release or major adverse cardiac 




The implications for practice would therefore be to make sense of available data from 
major trials and to provide recommendations for future research. It is also anticipated that 
the results from this review will inform better therapeutic practice, especially in the setting 
of low socio-economic countries like South Africa where cardiac catheterisation 










Participants:  Human participants with coronary artery disease. 
 
 
Intervention:  Remote ischaemic preconditioning or glucose-insulin-potassium either alone 
or as adjunctive therapy to revascularisation. 
 
Control:  Placebo or standard therapy alone. 
 
 








Primary objective: To determine whether participants receiving RIPC or GIK for coronary 
artery disease, and in particular STEMI, experience a reduction in mortality when 





1.   To determine whether participants receiving RIPC or GIK experience a reduction in 
infarct size, cardiac enzyme release or major adverse cardiac and cerebral events 
(MACCE) when compared to those patients not receiving them. 
2.   To identify adverse effects associated with RIPC or GIK therapy.. 
 
3.   To identify gaps in knowledge and where new trials are needed regarding the 











 Human participants with coronary artery disease 
 
 Intervention with RIPC or GIK either alone or in combination with 
revascularisation 
 




 Outcome measured by mortality, reduction in infarct size, cardiac enzyme 







We excluded studies that did not assess RIPC or GIK as part of therapy for coronary artery 




Search Strategy (Figure 3) 
 
 
Academic research, local and international studies were targeted. Language restrictions 
included studies published in English. Study identification included both manual and 
electronic searching strategies. Electronic searches involved the electronic databases 
Cochrane and PubMed. The initial selection criteria were broad to ensure that as many 
studies as possible were assessed in terms of their relevance to the review. Any articles 
that were obviously unsuitable were excluded in the early stages of the search (for 
example, on the basis of abstracts and titles presented in electronic catalogues), whilst the 
decision to exclude or include other articles was made once the article was been ordered 
and read. The number of articles included and excluded at the various stages was noted 
and shortlisted based on the quality of their content in association with the inclusion 
criteria. The reference lists of articles identified by this strategy were also searched and we 
selected those that were judged relevant. Several review articles were included because 
they provide comprehensive overviews that are beyond the scope of this review. 
 
 






The basic terms that were used when devising search strategies for electronic databases 
included “ischaemic preconditioning” or “ischemic preconditioning” and “glucose-insulin- 




A ‘search diary’ was maintained detailing the names of the databases searched, the 
keywords used and the search results. Titles and abstracts of studies considered for 
retrieval were recorded on a database, along with details of where the reference has been 
found. Inclusion/exclusion decisions were recorded on that database. Retrieved studies 





Data collection, storage and analysis 
 
 
Data was stored on an electronic database and reviewed based on the inclusion and 
exclusion criteria mentioned above. 
 
 
All relevant material identified from the above search were analysed. After reading the 
titles and abstracts of the identified articles, we acquired the full text articles deemed to 
meet the inclusion criteria. These articles were independently inspected to verify that they 
met the pre-specified inclusion criteria. 
 
 
Data was then extracted using a standardised data extraction form (Appendix 1). Any 








 Administrative details: trial identification number; title; author(s); 
published or unpublished; year of publication; number of studies included 
in paper; year in which the study was conducted; and details of other 
relevant papers cited 
 
 
 Verification assessment: assessment to ensure that the study met the 
inclusion criteria for the systematic review, details of study 
 
 
 Study design; duration and completeness of follow-up; country and 






 Risk of bias assessment: adequate sequence generation, allocation 
concealment, free of selective reporting, free of other bias, blinding 
 
 





















Regular meetings were conducted with the supervisor Prof. Lionel H Opie at the Hatter 
Cardiovascular Research Institute where progress was monitored and critique obtained. 
Additional input was received from Dr. Mark Engel at the University of Cape Town. 
 
 
Limitations of study 
 
 
Studies have been selected in English only. The available studies on RIPC and GIK are fairly 
















There is no particular ethics breach associated with the project and ethics approval is not 






















Electronic search of databases 
 












Articles screened by title and /or 
abstract = 100 














Articles screened by full text 
review = 15 
Articles excluded = 9 
Reasons: 
Unrelated to RIPC/GIK 
Unrelated to MI 
Not randomised 















Included articles = 6 
RIPC = 4 















The search strategy identified 100 articles from 2 databases.  Following review of the titles, 
 
85 articles were excluded, leaving 15 studies for full-text review. Reasons for exclusion 
were studies that were unrelated to RIPC/GIK, unrelated to CAD, not randomised and low 
powered. Reasons for exclusion are shown in Table 5  (Appendix 2). Six articles were 
included in the final subset. Studies were located in America, Europe and the United 
Kingdom with sample sizes ranging between 45 and 20201 participants. Interventions 
included RIPC and GIK either alone or as adjunctive therapy to patients with CAD. Studies 
evaluated for the purpose of the systematic review were exclusively human studies (Figure 
3) although a brief description of laboratory based animal studies are reported on to 
highlight the evolution of these therapies from the laboratory to clinical practice. The 
characteristics for inclusion were studies that were adequately powered, ideally placebo 





RIPC in Animal Studies 
 
 
Murray et al. first postulated the concept of ischaemic preconditioning in 1986 when they 
reported that episodes of sub-lethal regional ischaemia separated by periods of 
reperfusion for 40 minutes in the canine myocardium delayed the development of 
myocardial infarction.32 It was proposed that the potential for cardio-protective benefit 
was attributable to reduced ATP depletion by decreasing ATP demand during periods of 
ischaemia as well as by reducing the accumulation of toxic metabolites. They asserted that 
slowing the rate of myocardial necrosis could thereby extend the window period for 




Opie subsequently coined the term “reperfusion injury” in 1989 and elaborated on its effect 
in myocardial function.11 He explained that the two most important hypotheses in 
reperfusion injury included calcium overload, which interferes with mitochondrial 
oxygenation and ATP production, and free radical damage – a process that is accelerated 
during reperfusion. The consequences of this may be the basis for reperfusion arrhythmias, 
vascular damage and myocardial stunning.33,34,35,36,37 This concept was tested for remote or 
distant areas of myocardium the 1990s by Pryzklenk who showed that the final infarct size 
in the hearts of dogs was reduced up to 35% by inducing brief periods of ischaemia in the 
circumflex artery following left anterior descending artery occlusion.38 It was considered 
plausible that a systemic factor was responsible for mediating the preconditioning 
response. Amidst the growing interest elicited, subsequent human studies attempted to 





RIPC in Coronary Artery Bypass Grafting (CABG) 
 
 
Hausenloy et al demonstrated in a small study of 57 patients that the total troponin T 
 
released 72 h after surgery was reduced from 36.12 μg/L (26.08) in control group to 20.58 
 
μg/L (9.58) in the group treated with RIPC. The mean difference of 15.55 correlated with a 
43% reduction in troponin T release (95% CI 4.88-26; p=0.005).39 RIPC consisted of three 
5-min cycles of right upper limb ischaemia, induced by an automated cuff -inflator placed 
on the upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion 
during which the cuff was deflated whereas the control group had only a deflated cuff 
placed around the arm. 
 
 
Similar results were obtained with Venugopal et al in 2009 in a small but positive study of 
 
45 patients receiving coronary artery bypass with cold blood cardioplegia.40 RIPC was 
administered in the same manner. The total troponin T released 72 h after surgery, was 
reduced from a mean of 31.53 (24.04) mg/L in controls to 18.16 (6.67) mg/L with RIPC 
(mean difference 13.37 mg/lL , 95% CI 2.41 to 24.33 mg/L, p=0.019) which translates to a 




The ERICCA trial is a multi-centre, randomized, double-blinded, placebo-controlled clinical 
trial that is currently underway, which will recruit 1610 high-risk patients undergoing 
CABG ± valve surgery with or without RIPC.41 The primary combined endpoint will be 
 
cardiovascular death, non-fatal myocardial infarction, coronary revascularization and 
stroke at 1 year. The findings, if positive, will have the potential to demonstrate that RIPC 






RIPC in Percutaneous Coronary Intervention (PCI) 
 
 
The most landmark study of RIPC as a complement to angioplasty was conducted by Botker 
in Denmark.42 333 randomised patients with first onset STEMI were enrolled, of which half 
received RIPC. In the RIPC group the primary endpoint of myocardial salvage at 30 days 
following PCI was assessed using myocardial perfusion imaging as the proportion of the 
area at risk salvaged by treatment. The RIPC group showed a median salvage index of 0.75 
vs. 0.57 in the control group without any associated increased risk (95% CI 0.01-0.22; 
p=0·0333). 
 
RIPC has also been studied in elective PCI. The CRISP trial investigated 242 randomly 
assigned patients with undetectable pre-procedural Troponin I (TnI) undergoing elective 
PCI.43 Subjects were randomized to receive remote IPC or to the control group before 
arrival in the catheter laboratory. For its primary end-point, the median TnI at 24 hours 
after PCI was lower in the RIPC compared with the control group (0.06 versus 0.16 ng/mL; 
p=0.04). Subjects who received remote IPC experienced less chest discomfort and ECG ST- 
segment deviation than control subjects. At 6 months, the major adverse cardiac and 
cerebral event (MACCE) rate was lower in the RIPC group (4 versus 13 events; 95% CI 0.12- 
0.82; p=0.018). Furthermore this benefit was sustained at 6 year follow up in 192 of the 
original 242 patients at 6 year follow up when MACCE remained lower in the RIPC group 




RIPC in Thrombolysis 
 
 
The role of RIPC as an adjunct to thrombolysis has never been adequately studied, and to 
date there are no published trials in this regard. Ironically, this is most pertinent to the 
South African setting where revascularisation is mainly given in the form of thrombolysis 









Table 3. RIPC as an adjunct to CABG, PCI & Thrombolysis 
STUDY PARTICPANTS INTERVENTION CONTROL OUTCOME 
CABG  
Hausenloy39 n=57 undergoing 
elective CABG 
3 five minute upper limb 
ischaemia with BP cuff 
inflated to 200mmHg 
Deflated cuff placed 
around the arm 
Trop T at 72 hours 
Interv. 27 Interv 20.58 
Control 30 Control 36.12 
Venugopal40 n=45  undergoing 
elective CABG 
3 five minute upper limb 
ischaemia with BP 
cuff inflated to 
200mmHg 
Deflated cuff placed 
around the arm 
Trop T at 72 hours 
Interv. 23 Interv. 18.16 
Control 22 Control 31.53 
PCI 
Botker42 n=333 with STEMI 4 five minute upper limb 
ischaemia with BP cuff 
inflated to 200mmHg 
Standard PCI therapy only Myocardial salvage index 
Interv. 167 Interv. 0.75 
Control 166 Control 0.57 
Hoole43,44 n=201 undergoing 
elective PCI 
(6mo follow up) 
3 five minute upper limb 
ischaemia with BP cuff 
inflated to 200mmHg 
Deflated cuff placed 
around the arm 
 Trop I at 24 
hours 
MACCE 
Interv. 104 Interv. 0.06 4 
Control 97 Control 0.16 13 
THROMBOLYSIS 








As will be discussed, over the past two decades there have been numerous studies and 
meta-analyses in the field of GIK as a cardio-protective therapy in acute myocardial 





GIK in Animal Studies 
 
 
Preclinical trials in animal models in the early 1970s mainly showed benefit of GIK in 
limiting myocardial necrosis.45 Furthermore the benefits of GIK were shown in a primate 
model within one hour of coronary ligation.46 GIK reduced the amount of circulating FFAs 
by 50% and final infarct size by 15%. The study emphasized the importance of early GIK 
administration during which period the opportunity for metabolic manipulation is greatest. 





GIK in Clinical Studies 
 
 
In 1997 a meta-analysis by Fath-Ordoubadi et al noted a 28 % reduction in mortality when 
GIK was administered to patients with ACS. Although the study was performed before the 
reperfusion era it made important inferences regarding GIK and led the authors to 
conclude that GIK had an important role in improving mortality after ACS.48 
 
The CREATE-ECLA trial, the largest of these studies, investigated the effects of GIK in 20201 
patients with STEMI.47 At 30 days, 976 control patients and 1004 GIK infusion patients died 
(HR 1.03; CI 95%; p=0.45). Furthermore, a neutral effect was demonstrated on cardiac 
arrest, cardiogenic shock and cardiac failure in those receiving GIK. The CREATE-ECLA trial 
however, was not double blinded nor placebo controlled. Flaws in its design also included a 
delay to GIK therapy (median time from symptom onset to treatment was approximately 
5.7 hours) and non-uniformity in additional pharmacological therapy, such as statins and 
supplemental insulin. Moreover, these results were not well documented. Due to a 








A meta-analysis by Kloner in 2008 studied 18 trials using both high and low dose GIK. He 
demonstrated that GIK led to an overall 18% reduction in mortality at 30 days.48 
Furthermore, this included studies on GIK performed at various times of onset after 
clinically diagnosed acute myocardial infarction. Although this is supportive of the GIK 
concept it does not directly give information as to the possible benefits of very early GIK 
therapy. It was recommended that future studies address the pitfalls of previous studies 
leaving the hypothesis that early GIK would reduce 30 day and 1 year mortality. 
 
The recent 2013 review by Grossman et al. assessed the mechanisms whereby early GIK 
was given to a variety of animal models with coronary ligation or induced ischaemia, or to 
patients with early AMI in which GIK was demonstrated to be protective.31 It was 
suggested that much of the clinical controversy relating to GIK was due its late application. 
The major benefit of GIK to act as a metabolic modulator they proposed, is when it is 
started within the first hours of symptom onset. In practical terms, this would best be 




GIK in The Ambulance 
 
 
Accordingly, the IMMEDIATE trial was launched to administer GIK in the ambulance.50 This 
randomised, double blinded placebo controlled trial enrolled 871 patients with all acute 
coronary syndromes across 13 US cities. In it, paramedics in the field ensured the early 
start-up of the administration of GIK during the very first hours of ACS and continued the 
infusion for 12 hours thereafter. The first aim of lowering the circulating FFA levels was 
achieved in that at 2 hours after the start up in the ambulance the mean FFA values in the 
placebo group were 781 mmol/L versus 480 mmol/L in the GIK group (95% CI 269-465; 
p<0.0001). The subset of patients with STEMI derived significant benefit in that cardiac 
arrest and in-hospital mortality occurred in 6.1% with GIK vs. 14.4% with placebo (95% CI 
0.18-0.82; p=0.01), although the primary end-point of progression to MI in those with 





Furthermore there was no increase in heart failure with GIK. LV infarct size was 
ameliorated from 12% with placebo to 3% with GIK (p=0.05). It should nonetheless be 
noted that the primary end point was not achieved because the initial NIH-approved study 
design was aimed at 15 450 patients to reach statistical significance but due to funding 
constraints only 871 patients were recruited thereby considerably lessening its statistical 
impact. Subsequently, Selker et al. recently published one-year outcomes after the 
IMMEDIATE trial, which demonstrated that for patients with STEMI, outcomes were 
significantly improved. HRs for 1 year mortality and the 3 composites of mortality, cardiac 
arrest, or heart failure hospitalization within 1 year were, respectively, 0.65 (95% CI 0.33 to 
1.27, p = 0.21), 0.52 (95% CI 0.30 to 0.92, p = 0.03), 0.63 (95% CI 0.35 to 1.16, p = 0.14), and 









Table 4. GIK as adjunctive therapy for Acute Coronary Syndromes 
STUDY PARTICIPANTS INTERVENTION  CONTROL OUTCOME 







GIK - 25% 
























and 80 mEq/L of 
KCL at 1.5 
mL/kg/hr for 24 
hours 
 
Interv. 1004 139 667 236 1721 
 









n=842 with ACS 
 
n=357 with STEMI 
 
GIK - 30% 
 




ACS STEMI subset 
 
regular insulin, 
and 80 mEq of 
KCl/L at 1.5 
mL/kg/hr for 12 
Mortality Progress- 
 










Interv. 411 Interv. 18 200 6 10 
hours 








As an adjunct to CABG, the studies by Hausenloy and Venugopal showed a 43 & 42% 
reduction in cardiac enzyme release respectively.39,40 Numerous studies have suggested 
that the release of cardiac enzymes post operatively is associated with myocardial injury 
and consequently greater morbidity and mortality (up to 4.9 fold increase in risk).51,52,53 




When administered to patients undergoing emergency PCI the landmark Botker study 
showed an improvement in myocardial salvage.42 Since a reduction in infarct size is a major 
determinant of prognosis, the study concluded that RIPC is a simple, low cost, effective 
therapy with a favourable safety profile in STEMI. 54 The CRISP study also corroborated the 
cardioprotective effect of RIPC as an adjunct to elective PCI and called on for larger scaled 
multi centred randomised controlled trials to be performed.43,44 
 
RIPC has thereby demonstrated consistent and positive benefits in both proof of principle 
experimental & clinical trials targeting biochemical pathways that had not been considered 
previously. The extraordinary simplicity associated with RIPC implies that even a 
paramedic, a junior medical officer or nurse in an emergency room can perform the BP cuff 
 
inflations. Thus it has become routine practice in Denmark to perform RIPC in patients with 
 
ACS in the ambulance en route to a health care facility. 
 
 
Trials investigating GIK demonstrated conflicting and mostly negative results but were 
confounded by many variables such as the fixed dose regimens administered, failure to 
consider the volume or metabolic status of the patient and, importantly, a lack of emphasis 
on the relationship between the time of delivery of GIK and reperfusion.47,55,56,57 The only 
study to address this adequately has been the IMMEDIATE trial.50 It demonstrated a 
reduction in in-hospital mortality, cardiac arrest and LV infarct size in the STEMI subset of 
patients. The study also emphasized the importance of start up time of GIK therapy as 
suggested by Grossman et al in their 2014 review of GIK.31 The IMMEDIATE trial is also the 




which GIK infusion was started within 1 hour of symptom onset thereby highlighting the 













As indicated, higher-powered studies are needed to firmly establish the role of RIPC and 
GIK in the management of CAD. RIPC in the setting of thrombolysis has also not been 
studied previously and is an area for further research. Furthermore, there should be large 
scale, double blinded, multi centred studies that compare RIPC with GIK and with the 
combination. In view of the different mechanisms of RIPC and GIK the hypothesis would be 








The incidence of CAD is increasing and traditional practice largely ignored the impact of 
ischemic reperfusion injury. Attention however is slowly shifting towards viewing 
myocardial infarction as not just a mechanical disease but also a metabolic one in which 
both ischaemia & ischaemic reperfusion contribute to cardiomyocyte injury. South 
Africa, and other developing countries are in a challenging position to use all available 
positive and safe therapies that confer benefit given its limitations in accessibility to 
angiographic facilities. RIPC or GIK should therefore be considered as part of an 
armamentarium of adjunctive treatment strategies, to curb ischemic reperfusion injury 
and augment the benefit of revascularisation. More large scale, multi-centered 
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